Current Report Filing (8-k)
July 08 2016 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): July 1, 2016
ROCK CREEK PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
(State or other jurisdiction of incorporation)
|
000-15324
(Commission File Number)
|
52-1402131
(IRS Employer Identification No.)
|
|
|
|
|
2040 Whitfield Avenue, Suite 300
Sarasota, Florida 34243
(Address of principal executive offices,
including zip code)
844-727-0727
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Item 5.02.
|
Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On July 1 and July
5, 2016, respectively, Mr. Scott Sensenbrenner and Ms. Sunitha Chundru Samuel resigned as directors of Rock Creek Pharmaceuticals,
Inc. (the “Company”). Neither of their resignations were due to a disagreement with the Company on any matter relating
to the Company’s operations, policies, or practices.
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ROCK CREEK PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Michael J. Mullan
|
|
|
Michael J. Mullan
|
|
|
Chairman of the Board and Chief Executive Officer
|
Date: July 8, 2016
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rock Creek Pharmaceuticals (CE) (USOTC:RCPIQ)
Historical Stock Chart
From Apr 2023 to Apr 2024